Sage Journals: Discover world-class research

Abstract

Escin is a triterpenoid saponin extracted from the fruit of Aesculus wilsonii Rehd. and Aesculus hippocastanum (Hippocastanaceae). Clinically, it is widely used in the treatment of edema induced by either trauma or surgery, as well as treating chronic venous insufficiency. The anti-inflammatory and antiedema effects of escin have been extensively investigated. This article systematically reviews the effects of escin on inflammation and gastrointestinal diseases, including its role in inflammation, as an antioxidant, and in inhibiting gastric acid secretion and promoting gastrointestinal movement, especially, the molecular mechanism. The advantages and potential uses of escin have also been discussed.

Keywords

escin triterpenoid anti-inflammatory gastrointestinal protection mechanisms

Escin is a naturally occurring triterpenoid extracted from the fruit of Aesculus hippocastanum (Hippocastanaceae), which is found worldwide, especially in Iran, China, Japan, USA, northern India, Asia Minor, and Europe.¹ Escin is also extracted from the seeds of Aesculus chinensis Bunge var. chekiangensis (Hu et Fang) Fang and Aesculus wilsonii Rehd. in China, Aesculus turbinata Bl. in Japan, and A. hippocastanum Linn. in Europe.^2

-6 It is the primary active component of hippocastanus extracts (HCE).^2,7 Escin is a triterpene saponin mixture consisting of 2 forms, α-escin and β-escin. When an aqueous solution of β-escin is heated at 100 °C, it changes into α-escin.⁵ Escin was first used in clinical practice in Germany as a natural medicine, Reparil, in which the active component is β-escin.⁸

In China, escin consists of the total saponin extracted from the traditional Chinese medicine, A. wilsonii Rehd., which is listed in the Chinese Pharmacopeia to relieve bloating and gastric pain. The main active ingredient of escin includes 4 forms, namely, escin A, B, C, and D (Figure 1). Escin A (escin Ia) and B (escin Ib) are called β-escin, whereas escin C (isoescin Ia) and D (isoescin Ib) are called α-escin. Escin sodium (C₅₅H₈₅O₂₄Na) injection, comprising the sodium salt of escin, is approved in China and is generally used to treat inflammation and edema caused by trauma or surgery.⁹ Escin has no serious side effects. The most common ones are phlebitis and allergic reactions when administered intravenously.¹⁰

Figure 1

Structure of escin.

Besides being traditionally used to treat edema^11,12 and chronic venous insufficiency,^13,14 a number of studies show that escin has pharmacological effects, such as anti-inflammatory,^13,15,16 gastrointestinal tract protective,¹⁷ and antitumor.^18,19 This article systematically reviews the anti-inflammatory and gastroprotective effects of escin.

Anti-Inflammatory Effects of Escin

The antiedema and anti-inflammatory effects of escin have been studied extensively. In the past decades, the anti-inflammatory effects of escin and its pharmacological mechanism of action have been actively explored. Table 1 lists the anti-inflammatory properties of escin.

Table 1

Anti-inflammatory Effect of Escin in Different Models.

Compounds	Doses/routes of administration	Model	Effects	Authors
Escin	i.v.:0.45 mg/kg,0.9 mg/kg	Cerebral edema induced by acute omethoate poisoning in Sprague-Dawley rats	Attenuates cerebral edema	Wang et al¹²
Sodium salt of escin	i.v.:0.45 mg/kg0.9 mg/kg1.8 mg/kg	Transient cerebral ischemia in mice	Attenuates ischemic brain injury	Zhang et al²⁰
Sodium salt of escin	i.v.:0.9 mg/kg1.8 mg/kg3.6 mg/kg	Lipopolysaccharide-induced lung injury in mice;lung injury is induced by methyl-parathion;pulmonary edema caused by phosgene;pulmonary edema caused by epinephrine in rats	Protects from severe acute lung inflammation;reduces mortality in rats after pulmonary edema	Fu et al, Pan et al, Gallelli et al^21 -23
Sodium salt of escin	i.v.:0.9 mg/kg1.8 mg/kg3.6 mg/kg	Liver injury induced by carbon tetrachloride and endotoxin;liver damage induced by organophosphate;liver damage caused by p-methylthiophosphate	Protects from LPS-induced liver injury	Jiang et al²⁴
Sodium salt of escin	p.o.:5 mg/kg/day10 mg/kg/day	Rheumatoid arthritis and pleuritis in bilaterally adrenalectomized rats	Reduces arthritic index	Zhang et al²⁵
Sodium salt of escin	i.v.:0.45 mg/kg0.9 mg/kg1.8 mg/kg	Acetic acid-induced increase in capillary permeability in mice;cotton pellet granuloma in rats	Alleviates capillary permeability;decreases granuloma weight;	Fu et al¹⁷
Sodium salt of escin	i.v.:2 mg/kg	Carrageenan-induced paw edema;acetic acid-induced capillary permeability	Alleviates paw edema;alleviates capillary; permeability	Wang et al¹⁶
Sodium salt of escin	i.v.:3.6 mg/kg SA daily for 6 consecutive days	Otitis media induced by peptidoglycan polysaccharide in Tlr 2^−/− mice	Mitigates the severity of otitis media	Zhang et al²⁶
Sodium salt of escin	i.g.:5 mg/kg10 mg/kg for 16 days	Adjuvant-induced arthritis in rats	Inhibits paw swelling; brings about a reduction in the arthritis index	Du et al²⁷

Abbreviations: i.g., intragastric; i.v., intravenous; p.o., orally.

Sodium salt of escin: consisting of A, B, C, and D and containing at least 65% of A and B.

Inflammation is the protective response of the body to stimuli, which refers to a defensive response of a living factor with a vascular system to a damaging factor and is the central link of the inflammatory process.²⁸ The local reactions of inflammation include edema, pain, and dysfunction. Fever and an increase in peripheral blood neutrophils are systemic reactions of inflammation. In fact, inflammation is a complex biological response of body tissues to both pathogens and physiological damage, which involves immune cells, blood vessel alterations, and molecular mediators. Cell stimulation triggers the expression of proinflammatory genes and downstream signaling, which, in turn, results in the release of proinflammatory cytokines and chemokines, such as tumor necrosis factor (TNF) and interleukin (IL)-1β, which have autocrine and paracrine effects leading to the local activation of macrophages and neutrophils. The activation of endothelial cells by proinflammatory cytokines leads to an increase in vascular permeability in the injured tissues, resulting in capillary leakage and vasodilation.

Inflammation can be categorized as acute and chronic. Accumulating evidence shows that escin can attenuate both acute and chronic inflammation. To study acute inflammation, the carrageenan-induced paw edema, xylene-induced ear edema, acute lung injury induced by endotoxins, and acetic acid-induced increase in vascular permeability and spinal cord injury mouse models have been used. On the other hand, animal models, including cotton pellet-induced granuloma in rats, rheumatoid arthritis (RA), osteoarthritis, and periodontitis, have been routinely used to study chronic inflammation.¹⁹

Effect of Escin on Acute Inflammation

Escin is effective in alleviating certain severe inflammation. Anti-inflammatory effects correspond with antiedema effects, as inflammation and edema are interrelated. Inflammatory edema occurs when protein-rich fluid leaks out of the blood vessels and collects in the interstitium.

Escin can reduce cerebral edema and the permeability of the blood-brain barrier, relieving brain edema caused by acute omethoate exposure.¹² Inflammation is an important manifestation representing a dysfunction in the blood-brain barrier. Microvascular endothelial cells exposed to TNF-α, IL-1β, and IL-6 increase paracellular permeability.²⁹ The changes in the TNF-α, IL-1β, and IL-6 levels in omethoate-poisoned rats are associated with the dysfunction of the blood-brain barrier. An increase in the levels of matrix metalloproteinase-9, cyclooxygenase-2, prostaglandin E₂, and TNF-α causes dysfunction of the blood-brain barrier. Treatment with escin decreases the TNF-α and brain water levels and alleviates histopathological changes associated with the permeability of the blood-brain barrier.¹² Cerebral ischemia is a cause of disability or even death in adults, and considerable evidence shows that inflammation significantly contributes to cerebral damage after ischemia.³⁰ Studies demonstrate that escin exerts neuroprotective effects in the middle cerebral artery occlusion rat model by reducing the migration of neutrophils and decreasing the protein expression of adhesion molecules (intercellular adhesion molecule-1 and E-selection).³¹ Later research showed that escin can also attenuate ischemic brain injury by increasing the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) and reducing malondialdehyde (MDA) levels. Escin has a neuroprotective effect on transient cerebral ischemia in mice. It not only protects hippocampal neurons but also promotes learning and memory recovery in the mouse model of cerebral ischemia.²⁰ A study shows that escin can significantly downregulate the gene expression of complement factor 3, TNF-α, and CD40 and upregulate the expression of granulocyte-macrophage colony-stimulating factor, indicating that escin can protect hippocampal neurons in mice with cerebral ischemia, which may be related to the regulation of certain inflammatory genes.²⁰ Spinal cord injury can be attenuated by escin treatment.³² Studies reveal that escin has significant neuroprotective effects and leads to better locomotor recovery.³³

Acute lung injury is induced by many factors and eventually leads to acute respiratory distress syndrome, which is associated with inflammation, which involves the recruitment and release of proinflammatory mediators. Eventually, these processes can cause acute respiratory distress syndrome. In methyl-parathion-induced lung injury, escin can downregulate the levels of inflammatory mediators such as NO, TNF-α, and IL-1β.³⁴ Escin also can enhance endogenous antioxidant capacity, upregulate glucocorticoid receptor (GR) expression, and increase the activities of SOD and glutathione peroxidase in the lung.³⁵ Escin exerts protective effects in severe acute lung inflammation, which can be demonstrated by the fact that escin reduces mortality in rats due to pulmonary edema caused by exposure to phosgene.²¹ Escin has a therapeutic effect on acute pulmonary edema caused by the epinephrine in rats, and its effect may be better than that of dexamethasone (4 mg/kg).^21,22 Escin (1.8 or 3.6 mg/kg) has a therapeutic effect on lung injury caused by endotoxins in rats, and the effect is equivalent to that of methylprednisolone (600 mg/kg).²² Escin also can abrogate oleic acid-induced acute lung injury in rats.³⁶ Escin can enhance endogenous antioxidant capacity, increase venous tension, upregulate GR expression, attenuate the inflammatory reaction, and thus, inhibit acute inflammation and reduce tissue damage.³⁵ The typical symptoms of coronavirus disease 2019 (COVID-19) include pneumonia and inflammatory exudates.³⁷ Escin has immense potential in the therapy of severe pneumonia^23,38; it can reduce the levels of exudates on acute inflammation, which results in an effect similar to that of glucocorticoids (GCs). However, escin has no obvious inhibitory effect on the immune system, which is an advantage over GCs.¹¹ Accumulating evidence suggests that sodium escin may be a potential compound to treat COVID-19 owing to its efficacy in alleviating acute lung injury and inflammation.

Further studies show that the combination of escin and GCs has synergistic anti-inflammatory effects in carrageenan-induced paw edema and pleuritis in bilaterally adrenalectomized rats.³⁹ Escin and prednisone have a synergistic effect in inhibiting paw swelling induced by adjuvant-induced arthritis.²⁷ The combination of escin and GCs can reduce the adverse effect of GC administration alone, such as drug resistance after long-term use and osteoporosis. The anti-inflammatory effect of escin is similar to that of diclofenac and dexamethasone (4 mg/kg).⁴⁰ Dexamethasone, a steroidal anti-inflammatory drug, is commonly used clinically to treat inflammatory diseases, and undesirable effects may occur after long-term treatment. Escin shows a better anti-inflammation ability than dexamethasone. It inhibits inflammation from 4 to 24 hours after treatment in carrageenan-induced paw edema and acetic acid-induced vascular permeability in rats.¹⁶ A study shows that escin has no adverse effect on the immune system, suggesting its superiority to GC. Escin is a potent anti-inflammatory drug with a long duration of effect without causing immunosuppression.^16,41 The anti-inflammatory effect of escin depends on GCs, which can be observed in adrenalectomized mice.⁴²

The liver is the primary organ for drug metabolism, and damage to the liver can severely affect health. Escin (1.8 or 3.6 mg/kg) can ameliorate liver injury induced by carbon tetrachloride and endotoxin.^43,44 Escin can also reverse organophosphate-induced liver damage. Liver damage caused by either p-methylthiophosphate or methyl parathion is reduced after escin administration, which is related to its antioxidant and anti-inflammatory effects.^34,45 Treatment with escin after liver injury can inhibit the migration of inflammatory cells, reduce the degree of necrosis, and decrease the activities of serum alanine aminotransferase and aspartate aminotransferase.^43,46 It can downregulate the inflammatory mediators, such as TNF-α, IL-1β, NO, and the expression of 11 beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the liver. It also upregulates GR expression and increases endogenous antioxidant capacity. However, escin has no effect on the expression of 11 beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the liver.²⁴ Alleviation of lung injury or liver damage caused by lipopolysaccharide (LPS) is associated with the upregulation of GR and the enhancement of endogenous antioxidant capacity after treatment with escin.

A study has explored the effects of otitis media induced by peptidoglycan polysaccharide (PGPS) in TLR2-deficient (Tlr 2^−/−) mice and reports that escin can alleviate the severity of otitis media and improve the function of the middle ear in Tlr 2^−/− mice. Therefore, these findings represent a new strategy in the treatment of otitis media.²⁶

Effect of Escin in Chronic Inflammation

The cotton pellet granuloma test is generally used to observe the effect of drugs on chronic inflammation. Sterile cotton pellets were implanted subcutaneously in the back of Sprague-Dawley rats, and escin was found to be able to significantly decrease granuloma weight when compared with that in the control animals,¹⁷ demonstrating that escin can inhibit chronic inflammation.

Furthermore, the occurrence of RA is associated with inflammation and autoimmunity. RA is an autoimmune disorder associated with inflammation. GCs are widely used in the treatment of RA in a clinical setting; however, the adverse effect of GCs may be severe. Escin combined with prednisone can significantly inhibit foot swelling, reduce synovial inflammation, and decrease adverse effects compared with those when GCs are used alone.²⁷ Studies also show that escin combined with a low dose of dexamethasone can reduce the arthritic index, serum IL-6, and TNF-α levels. Thus, the combination of escin and GCs shows synergistic antiarthritic efficiency and fewer adverse effects.²⁵

Escin is used in different forms in a clinical setting, including horse chestnut seed extract capsules (containing 50 or 75 mg escin) and Essaven gel (Hippocastani seminis extractum spissum, 83.5 mg/g escin).¹⁴ It is currently used clinically to cure edema and chronic venous insufficiency.⁴⁷

Mechanism of the Anti-Inflammatory Effect of Escin

Previous studies show that escin can affect the pituitary-adrenaline system and upregulate the release of adrenocorticotrophic hormone and GCs in rats, thereby exhibiting potential anti-inflammatory effects.⁴² The effects of escin can be attributed to an increase in the secretion of prostaglandin F2α (PGF2α) and GCs.⁴⁸

Recent studies have shown that the mechanism of escin in alleviating inflammation is related to the upregulation of GR expression, a decrease in 11β-HSD2 expression, and a reduction of GC inactivation in tissues, thus promoting the binding of GCs to the GR (Figure 2).²⁴ The activated GR transfers into the nucleus and combines with the reaction elements on DNA, thereby inhibiting the release of the inflammatory mediators (TNF-α, IL-1β, and IL-6), decreasing MDA, and promoting the release of antioxidation factors (SOD, glutathione, GPx).⁴⁹ On the other hand, escin can inhibit the activation of nuclear factor-kappa B (NF-κB) and further downregulate the expression of TNF-α, IL-1β, and certain other inflammatory mediators.⁵⁰ A decrease in TNF-α inhibits the expression of inducible nitric oxide synthase (iNOS) and decreases the production of NO. Changes in the levels of the inflammation and antioxidation factor, in turn, inhibit the activation of NF-κB.^20,50

Figure 2

Mechanism of escin in alleviating inflammation. 11β-HSD2, 11 beta-hydroxysteroid dehydrogenase type 2; CBG, Corticosteroid-binding globulin; GPx, glutathione peroxidase; GC, glucocorticoid; GR, glucocorticoid receptor; iNOS, inducible nitric oxide synthase; IL, interleukin; MDA, malondialdehyde; NO, nitric oxide; NF-κB, nuclear factor-kappa B; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-alpha.

GR is a ligand-dependent transcription factor, which is a member of the nuclear hormone receptor superfamily. GR is a major regulator of the immune system owing to its anti-inflammatory and immunosuppressive activity. Activated GR interacts with co-suppressor molecules to attenuate NF-κB-associated coactivator activity, thereby reducing histone acetylation, chromatin remodeling, and RNA polymerase II action. The upregulation of GR retains the physiological and therapeutic effects of endogenous and exogenous GCs and promotes the treatment of endotoxemia. Pretreatment with escin significantly increases the expression of GR, and this may be one of the mechanisms of alleviating inflammation. It has an advantage over non-steroidal anti-inflammatory drugs (NSAIDs) and GCs in the treatment of acute inflammation for gastrointestinal protection owing to fewer adverse effects.

The expression of iNOS in vivo is related to TNF-α and IL-1β. TNF-dependent iNOS expression requires NF-κB activation. Escin inhibits NF-κB activation and, therefore, decreases TNF-dependent iNOS expression.⁵¹

Escin inhibits the expression of p65 in the livers of LPS-treated mice, and it has also been demonstrated that escin significantly inhibits NF-κB expression. The mechanism may be related to the GR/NF-κB rather than the COX/PGF2α signaling pathway.^25,40 The anti-inflammatory effect of escin in periodontitis is associated with the downregulation of inflammatory factors (TNF-α, IL-1β, IL-6) and is related to the TLR2 signaling pathway.³² Escin does not affect wound healing and bone cell activity at the same time, which suggests that escin treatment does not delay the healing of wound tissues, as observed in the case of GC.

Protective Effects of Escin on the Digestive System

Gastric emptying time and gastrointestinal transit time are vital aspects related to the digestive system, which play an important role in determining the quality of life.^52,53 Gastrointestinal disorders are accompanied by rheumatological diseases,⁵⁴ sepsis,⁵⁵ and autoimmune diseases.⁵⁶

Escin can promote gastrointestinal motility, reduce postoperative intestinal adhesion and obstruction, and reduce gastric emptying. In addition, escin can protect the gastric mucosa and reduce the damage caused by indomethacin and alcohol (Figure 3).⁵⁷ The Chinese medicine, Aesculus wilsonii Rehd. has been shown to accelerate gastrointestinal motility and to have gastroprotective effects.

Figure 3

Effects of escin on the gastrointestinal mucosa and transit. 5-HT2, 5-hydroxytryptamine 2; CAT, catalase; DA, dopamine; GPx, glutathione peroxidase; NO, nitric acid; PG, prostaglandin; VCAM-1, vascular cell adhesion molecule-1; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-alpha.

Physiological and Pathological Significance of Gastrointestinal Motility and Mucous Membrane Injury

Gastrointestinal motility is an essential factor in maintaining the normal function of the gastrointestinal tract.⁵⁸ Increased peristalsis promotes gastric emptying. When the gastrointestinal mucosa is damaged, it interferes with digestion, absorption, barrier function, and causes secretion dysfunction and affects gastrointestinal motility.

Postoperative peritoneal adhesions are a common complication of abdominal surgery. Drugs, for example, acetylcholinesterase inhibitors, can cause gastrointestinal side effects. In some patients, adhesion causes intestinal obstruction and pain. Ileus is a common complication caused by intestinal adhesion and is usually accompanied by pain, nausea, vomiting, abdominal distension, and gastrointestinal spasms. Prokinetic drugs are widely used for the treatment of ileus clinically although they have undesirable side effects. NSAIDs and GCs are used to treat acute and chronic inflammations; however, they may cause gastrointestinal complications.⁵⁹

Effects of Escin on Gastrointestinal Motility

Escin can promote gastrointestinal transit, which reduces the incidence of ileus,⁶⁰ constipation,⁶¹ and postoperative adhesions.^17,62 A randomized, double-blind, controlled clinical trial investigated the effects of intravenous injection of escin on the bowels of patients undergoing abdominal surgery, which showed that escin can improve gastrointestinal transit in patients after surgery.¹⁷ Another clinical trial showed that escin can shorten the recovery time of gastrointestinal motility in patients undergoing colorectal surgery,⁶³ while there are also reports of escin being able to inhibit intestinal injury in cecal ligation and puncture (CLP).⁴⁸

Mastuda et al have shown that the acceleration in gastrointestinal transit is mediated by endogenous prostaglandin (PGs) and constitutive NO, especially at the dose of 25 mg/kg.^61,64 It is reported that 5-hydroxytryptamine 2 (5-HT2) receptors are widely distributed in the central and peripheral tissues.⁶⁵ The 5-HT2 receptor is directly stimulated causing contraction of the gastrointestinal smooth muscle and intestinal vascular smooth muscle.⁶¹ These receptor-mediated effects include the partial contraction of the ileum of Guinea pigs.⁶⁶ In 2000, Mastuda et al showed that pretreatment with reserpine, which depletes 5-HT, reduced the effect of escin on gastrointestinal transit in mice.⁶¹ Therefore, these results suggest that escin stimulates gastrointestinal transit by the binding of 5-HT to the 5-HT_2A receptor, which in turn leads to the release of NO and PGs. In addition, studies have confirmed that pretreatment with l-NAME (an inhibitor of constitutive and inducible NO synthase), but not with dexamethasone (an inhibitor of inducible NO synthase), damages the acceleration of gastrointestinal transit.⁶⁴ Consequently, it has been proven that constitutive NO, rather than inducible NO, mediates the acceleration of gastrointestinal transit after treatment using escin.⁶⁴ A pilot postoperative ileus study showed that escin promoted the recovery of gastrointestinal motility in patients after colorectal surgery.⁶³ This study showed that patients taking escin (5, 15, and 25 mg) have a shorter recovery time of gastrointestinal motility, especially those receiving a dose of 25 mg. Interestingly, some researchers believe that the sympathetic nerves are also involved in the acceleration of gastrointestinal transit by escin; however, the mechanism of action is unclear.⁵³

Escin Suppress Gastric Emptying

Studies show that escin can suppress gastric emptying in rats, especially at the dose of 25 mg/kg.^1,61,67 These findings are suggestive of escin inhibiting gastric emptying in patients with diabetes or obesity, which can lead to the control of postprandial blood glucose levels.^61,68 The higher the gastric emptying rate, the faster the absorption of food and the higher the postprandial blood glucose levels in patients with diabetes. Thus, a reduction in gastric emptying can extend the absorption of food after meals, thereby improving blood glucose control.⁵⁷

Similar to gastrointestinal transport, endogenous PGs are also involved in the inhibition of gastric emptying by escin. The effect of escin in inhibiting gastric emptying was reduced in mice pretreated with dl-α-methyl-p-tyrosine methyl ester hydrochloride (a tyrosine hydroxylase inhibitor), reserpine (a catecholamine depletor), and 6-hydroxydopamine hydrochloride (a dopamine depletor). These indications suggest that catecholamines, possibly dopamine (DA), are involved in the inhibition of gastric emptying by escin.⁶⁷ Capsaicin is widely used to cut off capsaicin-sensitive C fibers following which the neurotoxic capsaicin inhibits the afferent function of the central nervous system and its ability to release neuropeptides.⁶⁹ PGs are the major metabolites of arachidonic acid, and dopamine 2 (D2) receptor agonists may affect the release of arachidonic acid.⁶⁷ In conclusion, to a certain extent, capsaicin-sensitive sensory nerves (CPSNs) mediate the synthesis and release of dopamine that act through the central D2 receptor, leading to the release of PGs.⁶⁷ Additionally, studies show that the central nervous system is also involved in the inhibition of gastric emptying by escin and that the inhibition of gastric emptying induced by escin is attenuated in streptozotocin-pretreated mice.⁵³

The mechanism of escin on gastric emptying may be associated with dopamine. Dopamine is found in the central nervous system and stomach. Previous studies show that the inhibition of gastric emptying by escin is associated with CPSNs. Further studies show that the effect is mediated by CPSNs to promote dopamine production to activate the central D2 receptor, which promotes the release of PGs.⁶¹

Protective Effects of Escin on the Gastrointestinal Mucosa

Studies show that escin can reduce gastric lesions induced by ethanol in rats. Gastric lesions include gastric mucosal lesions and gastric ulcers. Indomethacin can cause gastric ulcers in mice,⁷⁰ while ethanol can cause gastric mucosal injury,^57,71 mucosal edema, epithelial bleeding, cell shedding, and inflammatory cell infiltration. Endogenous mediators, such as lipid peroxidation products, vasoactive amines, or peptides and oxygen-free radicals, are believed to be involved in the pathogenesis of gastric mucosal lesions. Nevertheless, these conditions can be prevented by the use of escin.

It has been shown that TNF-α levels are significantly increased after indomethacin exposure in mice, which in turn stimulate the expression of P-selectin and vascular cell adhesion molecule (VCAM)-1. However, escin reduces the levels of TNF-α, P-selectin, and VCAM-1 in gastric tissues.⁷¹ In addition, escin decreases gastric inflammation and neutrophil infiltration caused by indomethacin. These results demonstrate that escin inhibits neutrophil infiltration and subsequent inflammatory responses, thereby preventing gastric ulcers caused by indomethacin in mice.⁷² Furthermore, the levels of SOD, chloramphenicol acetyltransferase,⁷³ and GPx were significantly reduced by indomethacin in the gastric tissue of mice. SOD, CAT, and GPx activities were significantly increased when mice were treated with escin.⁷¹ These findings suggest that escin has protective effects on the oxidative damage of gastric tissue induced by indomethacin. In addition, it has been reported that the CPSN has a protective effect on ethanol-induced gastric mucosal injury in rats⁷²; as discussed previously, stimulation of the capsaicin-sensitive afferent nerves by capsaicin can indirectly induce the release of PGs. Moreover, studies show that escin can inhibit H⁺/K⁺ ATPase, reduce gastric acid secretion, increase the activity of SOD, CAT, and GPx, and decrease the levels of TNF-α and VCAM-1, thus protecting the ulcerous mucosa.⁴⁸ These findings confirm the protective effect of escin on the gastrointestinal tract (Figure 3).

Conclusion and Outlooks

Escin exhibits potent anti-inflammatory effects in acute and chronic inflammations. Based on existing evidence, escin can be described as having a long duration of action like GC, but without the adverse reactions associated with it. Escin exerts its effects on alleviating inflammation, mainly by regulating the GR, which is different from the mechanisms of action of GCs and NSAIDs. The effects of escin on the gastrointestinal tract are associated with both neuroendocrine regulation and anti-inflammation, which also help in explaining the therapeutic effects of traditional Chinese medicine, A. wilsonii Rehd. In future studies, the molecular mechanisms of escin regulating GR and its role in treating acute viral pneumonia need to be investigated.

Footnotes

Acknowledgments

The authors are grateful to all the reviewers who participated in the review during the preparation of this manuscript. The authors would like to thank associate Professor Tian Wang and MJEditor () for its linguistic assistance.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (No. 30772760) and the Taishan Scholar Project.

ORCID iD

Yunqi Yang

References

Yoshikawa

Murakami

Yamahara

Matsuda

. Bioactive saponins and glycosides. XII. Horse chestnut. (2): structures of escins IIIB, IV, V, and VI and isoescins Ia, Ib, and V, acylated polyhydroxyoleanene triterpene oligoglycosides, from the seeds of horse chestnut tree (Aesculus hippocastanum L., Hippocastanaceae). Chem Pharm Bull. 1998;46(11):1764-1769.doi:10.1248/cpb.46.1764

http://www.ncbi.nlm.nih.gov/pubmed/9845957

Chen

Yang

Guo

Lee

FS.

Wang

. Determination of four major saponins in the seeds of Aesculus chinensis Bunge using accelerated solvent extraction followed by high-performance liquid chromatography and electrospray-time of flight mass spectrometry. Anal Chim Acta. 2007;596(2):273-280.doi:10.1016/j.aca.2007.06.011

http://www.ncbi.nlm.nih.gov/pubmed/17631106

Kimura

Ogawa

Jisaka

Kimura

Katsube

Yokota

. Identification of novel saponins from edible seeds of Japanese horse chestnut (Aesculus turbinata Blume) after treatment with wooden ashes and their nutraceutical activity. J Pharm Biomed Anal. 2006;41(5):1657-1665.doi:10.1016/j.jpba.2006.02.031

http://www.ncbi.nlm.nih.gov/pubmed/16621416

Kimura

Ogawa

Ishihara

et al. Antioxidant activities and structural characterization of flavonol O-glycosides from seeds of Japanese horse chestnut (Aesculus turbinata BLUME). Food Chem. 2017;228:348-355.doi:10.1016/j.foodchem.2017.01.084

28317733

Sirtori

. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183-193.doi:10.1006/phrs.2001.0847

http://www.ncbi.nlm.nih.gov/pubmed/11529685

Michelini

FM.

Alché

LE.

Bueno

. Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hippocastanum extract. J Pharm Pharmacol. 2018;70(11):1561-1571.doi:10.1111/jphp.13002

http://www.ncbi.nlm.nih.gov/pubmed/30168142

Dutra

LS.

Leite

MN.

Brandão

MAF.

de Almeida

PA.

Vaz

FAS.

de Oliveira

MAL

. A rapid method for total Β-escin analysis in dry, hydroalcoholic and hydroglycolic extracts of Aesculus hippocastanum L. by capillary zone electrophoresis. Phytochem Anal. 2013;24(6):513-519.doi:10.1002/pca.2425

http://www.ncbi.nlm.nih.gov/pubmed/23508832

Piller

. A comparison of the effectiveness of some anti-inflammatory drugs on thermal oedema. Br J Exp Pathol. 1975;56(6):554-560.

Zhang

Chen

Zhao

Gan

. Clinical study of traumatic cerebral edema by treatment with β-sodium aescinate. Chin J Critical Care Med. 2004;06:10-11.

10.

Wang

. Comparative analysis of 552 cases of adverse drug reactions/events induced by sodium aescinate for injection and instructions. China Pharm. 2015;26(32):4515-4518.

11.

Wang

Yang

Liu

Zhang

. Clinical effects of joint application of β-sodium aescinate and mannitol in treating early swelling after upper limb trauma surgery. Exp Ther Med. 2016;12(5):3320-3322.doi:10.3892/etm.2016.3743

http://www.ncbi.nlm.nih.gov/pubmed/27882156

12.

Wang

Jiang

Han

et al. Escin attenuates cerebral edema induced by acute omethoate poisoning. Toxicol Mech Methods. 2011;21(5):400-405.doi:10.3109/15376516.2010.550337

http://www.ncbi.nlm.nih.gov/pubmed/21417632

13.

Pittler

MH.

Ernst

. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol. 1998;134(11):1356-1360.doi:10.1001/archderm.134.11.1356

http://www.ncbi.nlm.nih.gov/pubmed/9828868

14.

Dudek-Makuch

Studzińska-Sroka

. Horse chestnut – efficacy and safety in chronic venous insufficiency: an overview. Revista Brasileira de Farmacognosia. 2015;25(5):533-541.doi:10.1016/j.bjp.2015.05.009

15.

Idris

Mishra

Khushtar

. Phytochemical, ethanomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine. J Basic Clin Physiol Pharmacol. 2020;31(5):0115. doi:10.1515/jbcpp-2019-0115

32649293

16.

Wang

Zhang

Han

Zhu

Zhang

. Effects of escin on acute inflammation and the immune system in mice. Pharmacol Rep. 2009;61(4):697-704.doi:10.1016/S1734-1140(09)70122-7

http://www.ncbi.nlm.nih.gov/pubmed/19815952

17.

Hou

Jiang

Wang

Liu

. Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg. 2005;29(12):1614-1620.doi:10.1007/s00268-005-7870-5

http://www.ncbi.nlm.nih.gov/pubmed/16311848

18.

Harikumar

KB.

Sung

Pandey

MK.

Guha

Krishnan

Aggarwal

. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 2010;77(5):818-827.doi:10.1124/mol.109.062760

http://www.ncbi.nlm.nih.gov/pubmed/20103608

19.

Wang

Chen

et al. Escin-induced DNA damage promotes escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/γH2AX pathway. Acta Pharmacol Sin. 2018;39(10):1645-1660.doi:10.1038/aps.2017.192

http://www.ncbi.nlm.nih.gov/pubmed/29849127

20.

Zhang

Zhu

Wang

Fan

. Escin attenuates cognitive deficits and hippocampal injury after transient global cerebral ischemia in mice via regulating certain inflammatory genes. Neurochem Int. 2010;57(2):119-127.doi:10.1016/j.neuint.2010.05.001

http://www.ncbi.nlm.nih.gov/pubmed/20466027

21.

Wang

Tian

Jiang

Wang

. Application of aescin and its derivatives in the preparation and treatment of acute lung inflammation and edema. patent CN1548052. November 24, 2004.

22.

Pan

Niu

Wang

Zhang

. Effect of escin on acute inflammation of lung. China Pharm. 2010;13(3):321-323.

23.

Gallelli

Zhang

Wang

. Severe acute lung injury related to COVID-19 infection: a review and the possible role for escin. J Clin Pharmacol. 2020;60(7):815-825.doi:10.1002/jcph.1644

http://www.ncbi.nlm.nih.gov/pubmed/32441805

24.

Jiang

Xin

Wang

et al. Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. Phytomedicine. 2011;18(14):1276-1284.doi:10.1016/j.phymed.2011.06.011

http://www.ncbi.nlm.nih.gov/pubmed/21802269

25.

Zhang

Huang

et al. Network pharmacology based research on the combination mechanism between escin and low dose glucocorticoids in anti-rheumatoid arthritis. Front Pharmacol. 2019;10:280-280.doi:10.3389/fphar.2019.00280

http://www.ncbi.nlm.nih.gov/pubmed/30967782

26.

Zhang

Zheng

Sang

et al. Otitis media induced by peptidoglycan-polysaccharide (PGPS) in TLR2-deficient (Tlr2(-/-)) mice for developing drug therapy. Infect Genet Evol. 2015;35:194-203.doi:10.1016/j.meegid.2015.08.019

http://www.ncbi.nlm.nih.gov/pubmed/26296608

27.

Song

Zhang

. Combined treatment with low dose prednisone and escin improves the anti-arthritic effect in experimental arthritis. Int Immunopharmacol. 2016;31:257-265.doi:10.1016/j.intimp.2016.01.006

http://www.ncbi.nlm.nih.gov/pubmed/26773773

28.

Tasneem

Liu

Choudhary

MI.

Wang

. Molecular pharmacology of inflammation: medicinal plants as anti-inflammatory agents. Pharmacol Res. 2019;139:126-140.doi:10.1016/j.phrs.2018.11.001

http://www.ncbi.nlm.nih.gov/pubmed/30395947

29.

Wang

XH.

Liu

JT.

Cui

. Effect of beta-escin sodium on endothelial cells proliferation, migration and apoptosis. Vascul Pharmacol. 2008;49(4-6):158-165.doi:10.1016/j.vph.2008.07.005

http://www.ncbi.nlm.nih.gov/pubmed/18718875

30.

Cui

Wang

JQ.

Shi

et al. Nodal mitigates cerebral ischemia-reperfusion injury via inhibiting oxidative stress and inflammation. Eur Rev Med Pharmacol Sci. 2019;23(13):5923-5933.doi:10.26355/eurrev_201907_18337

http://www.ncbi.nlm.nih.gov/pubmed/31298343

31.

XM.

Zhang

Zeng

. Effects of sodium beta-aescin on expression of adhesion molecules and migration of neutrophils after middle cerebral artery occlusion in rats. Acta Pharmacol Sin. 2004;25(7):869-875.http://www.ncbi.nlm.nih.gov/pubmed/15210059

32.

Liu

Wang

Qiu

et al. Escin inhibits lipopolysaccharide-induced inflammation in human periodontal ligament cells. Mol Med Rep. 2012;6(5):1150-1154.doi:10.3892/mmr.2012.1031

http://www.ncbi.nlm.nih.gov/pubmed/22895831

33.

Selvakumar

GP.

Manivasagam

Rekha

KR.

Jayaraj

RL.

Elangovan

. Escin, a novel triterpene, mitigates chronic MPTP/p-induced dopaminergic toxicity by attenuating mitochondrial dysfunction, oxidative stress, and apoptosis. J Mol Neurosci. 2015;55(1):184-197.doi:10.1007/s12031-014-0303-x

http://www.ncbi.nlm.nih.gov/pubmed/24788336

34.

Wang

Jiang

et al. Protective effect of sodium aescinate on lung injury induced by methyl parathion. Hum Exp Toxicol. 2011;30(10):1584-1591.doi:10.1177/0960327110393764

http://www.ncbi.nlm.nih.gov/pubmed/21177729

35.

Xin

Zhang

Fan

Jiang

Wang

. Escin attenuates acute lung injury induced by endotoxin in mice. Eur J Pharm Sci. 2011;42(1-2):73-80.doi:10.1016/j.ejps.2010.10.008

http://www.ncbi.nlm.nih.gov/pubmed/21040784

36.

Wei

Tong

Wen-ping

et al. The impact of sodium aescinate on acute lung injury induced by oleic acid in rats. Exp Lung Res. 2011;37(10):585-599.doi:10.3109/01902148.2011.622426

http://www.ncbi.nlm.nih.gov/pubmed/22087513

37.

The Lancet . Emerging understandings of 2019-nCoV. Lancet. 2020;395(10221):311. doi:10.1016/S0140-6736(20)30186-0

31986259

38.

Salinas

FM.

Vázquez

Gentilini

et al. Aesculus hippocastanum L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation in vivo. Antiviral Res. 2019;164:1-11.doi:10.1016/j.antiviral.2019.01.018

http://www.ncbi.nlm.nih.gov/pubmed/30711418

39.

Xin

Zhang

Sun

et al. Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro . Phytomedicine. 2011;18(4):272-277.doi:10.1016/j.phymed.2010.08.013

http://www.ncbi.nlm.nih.gov/pubmed/20850956

40.

Wang

Zhang

Jiang

Wang

Chong

. Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway. Exp Ther Med. 2013;6(2):419-422.doi:10.3892/etm.2013.1128

http://www.ncbi.nlm.nih.gov/pubmed/24137201

41.

Zhang

Wang

Fan

et al. The potent anti-inflammatory agent escin does not increase corticosterone secretion and immune cell apoptosis in mice. Fitoterapia. 2011;82(6):861-867.doi:10.1016/j.fitote.2011.04.004

http://www.ncbi.nlm.nih.gov/pubmed/21596110

42.

Hiai

Yokoyama

Oura

. Effect of escin on adrenocorticotropin and corticosterone levels in rat plasma. Chem Pharm Bull. 1981;29(2):490-494.doi:10.1248/cpb.29.490

http://www.ncbi.nlm.nih.gov/pubmed/6268314

43.

Singh

Sidhu

Chopra

Khan

. The novel role of β-aescin in attenuating CCl₄-induced hepatotoxicity in rats. Pharm Biol. 2017;55(1):749-757.doi:10.1080/13880209.2016.1275023

http://www.ncbi.nlm.nih.gov/pubmed/28064552

44.

Cheng

Kuang

. Aescin reduces oxidative stress and provides neuroprotection in experimental traumatic spinal cord injury. Free Radic Biol Med. 2016;99:405-417.doi:10.1016/j.freeradbiomed.2016.09.002

http://www.ncbi.nlm.nih.gov/pubmed/27596954

45.

Wang

Jiang

et al. Sodium aescinate ameliorates liver injury induced by methyl parathion in rats. Exp Ther Med. 2012;3(5):818-822.doi:10.3892/etm.2012.479

http://www.ncbi.nlm.nih.gov/pubmed/22969975

46.

Cengiz

Kutlu

HM.

Peker Cengiz

Ayhancı

. Escin attenuates oxidative damage, apoptosis and lipid peroxidation in a model of cyclophosphamide-induced liver damage. Drug Chem Toxicol. 2020:1-8.doi:10.1080/01480545.2020.1810262

http://www.ncbi.nlm.nih.gov/pubmed/32838567

47.

Ottillinger

Greeske

. Rational therapy of chronic venous insufficiency-chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord. 2001;1:5 doi:10.1186/1471-2261-1-5

http://www.ncbi.nlm.nih.gov/pubmed/11747472

48.

Zhang

et al. Oral administration of escin inhibits acute inflammation and reduces intestinal mucosal injury in animal models. Evid Based Complement Alternat Med. 2015;2015:1-9.doi:10.1155/2015/503617

http://www.ncbi.nlm.nih.gov/pubmed/26199634

49.

Zhang

Wang

et al. Potent anti-inflammatory agent escin does not affect the healing of tibia fracture and abdominal wound in an animal model. Exp Ther Med. 2012;3(4):735-739.doi:10.3892/etm.2012.467

http://www.ncbi.nlm.nih.gov/pubmed/22969961

50.

Wang

YW.

Wang

SJ.

Zhou

YN.

Pan

SH.

Sun

. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo . J Cancer Res Clin Oncol. 2012;138(5):785-797.doi:10.1007/s00432-012-1152-z

http://www.ncbi.nlm.nih.gov/pubmed/22270965

51.

Maghsoudi

Hallajzadeh

Rezaeipour

. Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study. Clin Rheumatol. 2018;37(9):2471-2478.doi:10.1007/s10067-018-4097-z

http://www.ncbi.nlm.nih.gov/pubmed/29663159

52.

Gyger

Baron

. Systemic sclerosis: gastrointestinal disease and its management. Rheum Dis Clin North Am. 2015;41(3):459-473.doi:10.1016/j.rdc.2015.04.007

http://www.ncbi.nlm.nih.gov/pubmed/26210129

53.

Matsuda

Yoshikawa

. Effects of escins Ia, Ib, IIA, and IIb from horse chestnuts on gastrointestinal transit and ileus in mice. Bioorg Med Chem. 1999;7(8):1737-1741.doi:10.1016/S0968-0896(99)00100-5

http://www.ncbi.nlm.nih.gov/pubmed/10482465

54.

Kröner

PT.

Tolaymat

OA.

Bowman

AW.

Abril

Lacy

. Gastrointestinal manifestations of rheumatological diseases. Am J Gastroenterol. 2019;114(9):1441-1454.doi:10.14309/ajg.0000000000000260

http://www.ncbi.nlm.nih.gov/pubmed/31205138

55.

Nguyen

HB.

Smith

. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med. 2007;25(5):564-571.doi:10.1016/j.ajem.2006.08.015

http://www.ncbi.nlm.nih.gov/pubmed/17543662

56.

Collins-Yoder

. Gastrointestinal manifestations of autoimmune diseases requiring critical care. Crit Care Nurs Clin North Am. 2018;30(1):1-12.doi:10.1016/j.cnc.2017.10.001

http://www.ncbi.nlm.nih.gov/pubmed/29413204

57.

Matsuda

Yoshikawa

. Gastroprotections of escins Ia, Ib, IIA, and IIb on ethanol-induced gastric mucosal lesions in rats. Eur J Pharmacol. 1999;373(1):63-70.doi:10.1016/S0014-2999(99)00249-6

http://www.ncbi.nlm.nih.gov/pubmed/10408252

58.

Vancamelbeke

Vermeire

. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821-834.doi:10.1080/17474124.2017.1343143

http://www.ncbi.nlm.nih.gov/pubmed/28650209

59.

Harirforoosh

Asghar

Jamali

. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-847.doi:10.18433/J3VW2F

http://www.ncbi.nlm.nih.gov/pubmed/24393558

60.

Holte

Kehlet

. Postoperative ileus: a preventable event. Br J Surg. 2000;87(11):1480-1493.doi:10.1046/j.1365-2168.2000.01595.x

http://www.ncbi.nlm.nih.gov/pubmed/11091234

61.

Matsuda

Yoshikawa

. Possible involvement of 5-HT and 5-HT2 receptors in acceleration of gastrointestinal transit by escin Ib in mice. Life Sci. 2000;66(23):2233-2238.doi:10.1016/S0024-3205(00)00551-8

http://www.ncbi.nlm.nih.gov/pubmed/10855943

62.

Bougelet

Roland

IH.

Ninane

Arnould

Remacle

Michiels

. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol. 1998;345(1):89-95.doi:10.1016/S0014-2999(97)01616-6

http://www.ncbi.nlm.nih.gov/pubmed/9593599

63.

Xie

Zong

et al. Pilot postoperative ileus study of escin in cancer patients after colorectal surgery. World J Surg. 2009;33(2):348-354.doi:10.1007/s00268-008-9816-1

http://www.ncbi.nlm.nih.gov/pubmed/19052813

64.

Matsuda

Yoshikawa

. Roles of endogenous prostaglandins and nitric oxide in inhibitions of gastric emptying and accelerations of gastrointestinal transit by escins Ia, Ib, IIA, and IIb in mice. Life Sci. 2000;66(3):41-46.http://www.ncbi.nlm.nih.gov/pubmed/10666004

65.

Bradley

PB.

Engel

Feniuk

et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986;25(6):563-576.doi:10.1016/0028-3908(86)90207-8

http://www.ncbi.nlm.nih.gov/pubmed/2875415

66.

Buchheit

KH.

Engel

Mutschler

Richardson

. Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol. 1985;329(1):36-41.doi:10.1007/BF00695189

http://www.ncbi.nlm.nih.gov/pubmed/2582276

67.

Matsuda

Yoshikawa

. Possible involvement of dopamine and dopamine2 receptors in the inhibitions of gastric emptying by escin Ib in mice. Life Sci. 2000;67(24):2921-2927.doi:10.1016/S0024-3205(00)00876-6

http://www.ncbi.nlm.nih.gov/pubmed/11133004

68.

Matsuda

Murakami

Yamahara

Yoshikawa

. Mode of action of escins Ia and IIa and E,Z-senegin II on glucose absorption in gastrointestinal tract. Bioorg Med Chem. 1998;6(7):1019-1023.doi:10.1016/S0968-0896(98)00054-6

http://www.ncbi.nlm.nih.gov/pubmed/9730238

69.

Kollarik

Dinh

QT.

Fischer

Undem

. Capsaicin-sensitive and -insensitive vagal bronchopulmonary C-fibres in the mouse. J Physiol. 2003;551(Pt 3):869-879.doi:10.1113/jphysiol.2003.042028

http://www.ncbi.nlm.nih.gov/pubmed/12909686

70.

Marhuenda

Alarcón de la Lastra

Martín

. Antisecretory and gastroprotective effects of aescine in rats. Gen Pharmacol. 1994;25(6):1213-1219.doi:10.1016/0306-3623(94)90140-6

http://www.ncbi.nlm.nih.gov/pubmed/7875547

71.

Kvietys

PR.

Twohig

Danzell

Specian

. Ethanol-induced injury to the rat gastric mucosa. Role of neutrophils and xanthine oxidase-derived radicals. Gastroenterology. 1990;98(4):909-920.doi:10.1016/0016-5085(90)90015-s

http://www.ncbi.nlm.nih.gov/pubmed/2311875

72.

Uchida

Yano

Watanabe

. The role of capsaicin-sensitive afferent nerves in protective effect of capsaicin against absolute ethanol-induced gastric lesions in rats. Jpn J Pharmacol. 1991;55(2):279-282.doi:10.1254/jjp.55.279

http://www.ncbi.nlm.nih.gov/pubmed/2067143

73.

van Asch

CJ.

Luitse

MJ.

Rinkel

GJ.

van der Tweel

Algra

Klijn

. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167-176.doi:10.1016/S1474-4422(09)70340-0

http://www.ncbi.nlm.nih.gov/pubmed/20056489

Anti-Inflammatory and Gastroprotective Effects of Escin

Abstract

Keywords

Anti-Inflammatory Effects of Escin

Effect of Escin on Acute Inflammation

Effect of Escin in Chronic Inflammation

Mechanism of the Anti-Inflammatory Effect of Escin

Protective Effects of Escin on the Digestive System

Physiological and Pathological Significance of Gastrointestinal Motility and Mucous Membrane Injury

Effects of Escin on Gastrointestinal Motility

Escin Suppress Gastric Emptying

Protective Effects of Escin on the Gastrointestinal Mucosa

Conclusion and Outlooks

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

ORCID iD

References